source
- Scribe Therapeutics launches first gene‑editing IPO in over two years, targeting high‑cholesterol geneScribe Therapeutics, a gene‑editing biotech based in California, announced its initial public offering, the first for a CRISPR‑focused company in more than two years. The company, founded by resea…
- Latigo Biotherapeutics raises $345.6M in IPO to fund non-opioid pain drug pipelineLatigo Biotherapeutics, a Los Angeles-based biotech focused on non-opioid ion-channel-blocking pain therapies, completed an initial public offering on Thursday. The company sold 19.2 million share…